Article: WEX Receives No Objection Letter From Health Canada for Phase III Clinical Trial in Cancer Pain

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - June 13, 2007) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) is pleased to announce that the Company has received a No Objection Letter from Health Canada for conducting a Phase III clinical trial in cancer pain for its lead product, Tectin(TM).

This multi-centre, randomized, double-blind, and placebo- controlled trial (TEC-006) will include approximately 120 patients with moderate to severe cancer-related pain. The study design is based on the Company's knowledge and experience obtained from the WEX- 014 trial. A primary composite endpoint that evaluates pain reduction with an improvement in quality of life will be used to define ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!